{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
icosapent ethyl
to a specific field?
Status:
Investigational
Source:
INN:clodoxopone [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Clodoxopone (LR 19731) is a hypoglycemic agent, developed in the 1980s by Italian company Lusofarmaco. In animal models, the drug lowered the plasma cholesterol and triglyceride levels in several experimental conditions after single or repeated treatments. Results of the clinical trials of the drug are not reported.
Status:
Investigational
Source:
NCT00244751: Phase 2 Interventional Completed Cirrhosis, Liver
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Farglitazar is a non-thiazolidinedione insulin sensitizer and agonist of peroxisome proliferator-activated receptor-gamma. GlaxoSmithKline was developing farglitazar for the treatment of liver fibrosis and Type 2 diabetes mellitus.
Class (Stereo):
CHEMICAL (RACEMIC)
Amicibone is an antitussive agent.
Status:
Investigational
Source:
NCT00486876: Phase 2 Interventional Completed Irritable Bowel Syndrome
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Dextofisopam, a non-serotonergic agent currently being evaluated for the treatment of irritable bowel syndrome (IBS), is the R-enantiomer of racemic tofisopam, a molecule marketed and used safely outside the United States for over three decades for multiple indications including IBS. Dextofisopam represents a novel, first-in-class opportunity with a positive proof-of-concept study in an arena where there are few compounds with unique approaches or positive efficacy results. By structure, Dextofisopam is a member of the homophthalazine class; Dextofisopam binds to specific receptors in areas of the brain affecting autonomic function, including gastrointestinal (GI) function. Unlike the two 5-HT3 or 5-HT4 mediated IBS therapies currently available, both with significant safety concerns, Dextofisopam novel non-serotonergic activity offers a unique and innovative approach to IBS treatment. Recent studies have indicated that
dextofisopam binds to a novel binding site within the
central nervous system that may be responsible for
mediating its actions. This receptor has been characterized
as the 2,3-benzodiazepine receptor, which is
distinct from the classical 1,4 or 1,5-benzodiazepine
receptor. Dextofisopam has no significant binding at
other receptors or ion channels
Status:
Investigational
Source:
NCT00068952: Phase 3 Interventional Completed Glioblastoma
(2003)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Edotecarin (J-107088 or [6-N-(1-hydroxymethyl-2-hydroxy)ethylamino-12,13-dihydro-2,10-dihydroxy- 13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]-pyrrolo[3,4-c]-carb azo le-5,7(6H)-dione]) is a DNA topoisomerase I inhibitor. The antitumor activity of edotecarin has been tested in vitro and in vivo, and inhibition of tumor growth has been observed in breast, cervix, pharynx, lung, prostate, colon, gastric, and hepatic cancer models. Banyu Pharmaceutical Co Ltd and Pfizer Inc were developing edotecarin for the potential treatment of solid tumors. Edotecarin development has been discontinued.
Status:
Investigational
Source:
INN:impromidine [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Impromidine is a highly potent and specific histamine H2 receptor agonist used diagnostically as a gastric secretion indicator. The value of impromidine as an effective acid-secretory stimulant is limited by its tendency to cause cardiovascular side-effects, that mediated by H2-receptors in the cardiovascular system.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Palosuran, also known as ACT-058362, a potent and specific antagonist of
the human UT receptor. Urotensin inhibition with palosuran was a promising alternative in pulmonary arterial hypertension. Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues. Palosuran improves pancreatic and renal function in diabetic rats. Phase-II clinical trials for diabetic nephropathies and cardiovascular disorders were discontinued.
Status:
Investigational
Source:
NCT01067339: Phase 3 Interventional Completed Endothelial Dysfunction
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Darapladib (SB-435495), as reversible inhibitors of lipoprotein-associated phospholipase A(2) (Lp-PLA(2) has been developed and studies for the potential treatment of atherosclerosis. In November 2013, GSK announced that the drug had failed to meet Phase III endpoints in a trial of 16,000 patients with acute coronary syndrome.
Class (Stereo):
CHEMICAL (ACHIRAL)
FLUFYLLINE, a theophylline derivative, has a long-lasting blood pressure lowering activity as well as remarkable serotonin- and histamine antagonism and broncholytic activity.
Status:
Investigational
Source:
INN:ethyl dibunate [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Ethyl dibunate is a non-narcotic antitussive agent.
